Daiichi Sankyo Says Ranbaxy Purchase Deteriorated Its Balance Sheet
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo expects the strong yen could reduce third- and fourth-quarter sales by ¥9 billion, but that for fiscal year 2008, the decrease will be pared by greater than expected performance of its Luipold Pharmaceutical subsidiary